These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 32583706)

  • 1. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers.
    Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS
    Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between Physical Activity/Heart Rate Variability Data Obtained Using a Wearable Device and Timed Motor Functional Tests in Patients with Duchenne Muscular Dystrophy: A Pilot Study.
    Nakamura A; Matsumura T; Takeshima Y; Kuru S; Imazaki M; Nonomura H; Kaiya H
    J Neuromuscul Dis; 2024; 11(3):715-724. PubMed ID: 38607760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between neurodevelopmental impairments and motor function in Duchenne muscular dystrophy.
    Thangarajh M; McDermott MP; Guglieri M; Griggs RC
    Ann Clin Transl Neurol; 2023 Dec; 10(12):2285-2296. PubMed ID: 37804000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appendicular lean mass index and motor function in ambulatory patients with Duchenne muscular dystrophy.
    Kiefer M; Townsend E; Goncalves C; Shellenbarger KC; Gochyyev P; Wong BL
    Muscle Nerve; 2024 Aug; 70(2):226-231. PubMed ID: 38837739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
    Rabbia M; Guridi Ormazabal M; Staunton H; Veenstra K; Eggenspieler D; Annoussamy M; Servais L; Strijbos P
    J Neuromuscul Dis; 2024; 11(3):701-714. PubMed ID: 38640165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gait Characterization in Duchenne Muscular Dystrophy (DMD) Using a Single-Sensor Accelerometer: Classical Machine Learning and Deep Learning Approaches.
    Ramli AA; Liu X; Berndt K; Goude E; Hou J; Kaethler LB; Liu R; Lopez A; Nicorici A; Owens C; Rodriguez D; Wang J; Zhang H; Aranki D; McDonald CM; Henricson EK
    Sensors (Basel); 2024 Feb; 24(4):. PubMed ID: 38400281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Gross Motor Milestones in Duchenne Muscular Dystrophy.
    Norcia G; Lucibello S; Coratti G; Onesimo R; Pede E; Ferrantini G; Brogna C; Cicala G; Carnicella S; Forcina N; Fanelli L; Pane M; Mercuri E
    J Neuromuscul Dis; 2021; 8(4):453-456. PubMed ID: 33935100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A qualitative study to understand the Duchenne muscular dystrophy experience from the parent/patient perspective.
    Brown V; Merikle E; Johnston K; Gooch K; Audhya I; Lowes L
    J Patient Rep Outcomes; 2023 Dec; 7(1):129. PubMed ID: 38085412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy.
    Mercuri E; Coratti G; Messina S; Ricotti V; Baranello G; D'Amico A; Pera MC; Albamonte E; Sivo S; Mazzone ES; Arnoldi MT; Fanelli L; De Sanctis R; Romeo DM; Vita GL; Battini R; Bertini E; Muntoni F; Pane M
    PLoS One; 2016; 11(8):e0160195. PubMed ID: 27494024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Landfeldt E; Alemán A; Abner S; Zhang R; Werner C; Tomazos I; Ferizovic N; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2024; 11(3):579-612. PubMed ID: 38669554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study.
    Muntoni F; Signorovitch J; Sajeev G; Done N; Yao Z; Goemans N; McDonald C; Mercuri E; Niks EH; Wong B; Vandenborne K; Straub V; de Groot IJM; Tian C; Manzur A; Dieye I; Lane H; Ward SJ; Servais L; ; ; ; ;
    PLoS One; 2024; 19(7):e0304984. PubMed ID: 38985784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
    Muntoni F; Byrne BJ; McMillan HJ; Ryan MM; Wong BL; Dukart J; Bansal A; Cosson V; Dreghici R; Guridi M; Rabbia M; Staunton H; Tirucherai GS; Yen K; Yuan X; Wagner KR;
    Neurol Ther; 2024 Feb; 13(1):183-219. PubMed ID: 38190001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timed rolling and rising tests in Duchenne muscular dystrophy ambulant boys: a feasibility study.
    Sobierajska-Rek A; Jabłońska-Brudło J; Dąbrowska A; Wojnicz W; Meyer-Szary J; Wierzba J
    Minerva Pediatr (Torino); 2024 Apr; 76(2):208-216. PubMed ID: 38639735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
    Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP
    Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?
    Buckon C; Sienko S; Bagley A; Sison-Williamson M; Fowler E; Staudt L; Heberer K; McDonald CM; Sussman M
    PLoS Curr; 2016 Jul; 8():. PubMed ID: 27500011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a new instrument to evaluate gait characteristics of individuals with Duchenne Muscular Dystrophy: Gait Assessment Scale for Duchenne Muscular Dystrophy, and its validity and reliability.
    Aydın Yağcıoğlu G; Alemdaroğlu Gürbüz İ; Topuz S; Yılmaz Ö
    Early Hum Dev; 2023 Oct; 185():105843. PubMed ID: 37672897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a 5-Week Virtual Reality Telerehabilitation Program for Children With Duchenne and Becker Muscular Dystrophy: Prospective Quasi-Experimental Study.
    Baeza-Barragán MR; Labajos Manzanares MT; Amaya-Álvarez MC; Morales Vega F; Rodriguez Ruiz J; Martín-Valero R
    JMIR Serious Games; 2023 Nov; 11():e48022. PubMed ID: 37990809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
    Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
    Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.